ArticleScientific reports2026
First evidence for isolation and characterization of Bacopa monnieri (L.) Wettst-derived nanovesicles with anti-neuroblastoma potential.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ayurvedic Medicinal Plants and Plant-Derived Extracellular Vesicles: Current Evidence and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Edible plant-derived nanovesicles (PDNVs) have emerged as promising nanotherapeutic strategies for various diseases, including cancer. The biochemical composition and functional properties of PDNVs vary considerably on the basis of their botanical source. Bacopa monnieri (L.) Wettst is a medicinal plant renowned for its rich phytochemical profile, yet the isolation and biological activities of B. monnieri -derived nanovesicles (BMNVs) remain unexplored. We report, for the first time, the isolation, molecular cargo profiling, and in vitro functional evaluation of BMNVs against neuroblastoma cells. The isolated BMNVs displayed a characteristic bilayer morphology with an average particle size of ~ 112 nm. Mass spectrometry-based metabolite analysis revealed that triterpenoids and triterpene saponins are predominant compound classes detected in BMNVs, whereas protein cargo analysis revealed superoxide dismutase, which is correlated with their intrinsic free radical scavenging activities. In vitro assays demonstrated that BMNVs significantly suppress neuroblastoma cell growth and induce morphological alterations. Confocal three-dimensional reconstruction confirmed the cellular internalization of the BMNVs, revealing a distinct perinuclear distribution. This study provides the first evidence of the use of BMNVs as bioactive carriers, highlighting their potential as novel nanotherapeutic agents and establishing B. monnieri as a valuable natural resource for the development of bioactive plant-derived nanovesicles for nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.